About InventisBio

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas. Prior to the Series B financing, the company received investment from angel investors led by Beautiful Mind Investment Management Ltd in 2015 and Series A financing led by Lilly Asia Venture and SinoPharm Capital in May 2016, totaling USD11 million.
Founder and CEO: Yaolin Wang

3 articles with InventisBio